News & Perspective

Mar 30, 2018

Mar 30, 2018

ASP Scan (Weekly) for Mar 30, 2018

Statewide hospital stewardship
New class of synthetic antibiotics
Candida auris in Europe
Experimental C diff drug
Urine culture and prescribing
MRSA, VRE contact precautions
Resistant Acinetobacter in SE Asia
Infection prevention and antibiotic stewardship
Cornerstones of stewardship
Resistant Acinetobacter in kids
C diff prediction tool
Perceived AMR risk in Germany

Feb 09, 2018

Feb 09, 2018

ASP Scan (Weekly) for Feb 09, 2018

Research agenda for antibiotic resistance
Antibiotics for aspiration pneumonitis
Stewardship in kids' pneumonia
Resistant yaws
Antibiotic-resistant Campylobacter
Antimicrobial prescribing survey
Antibiotic-resistant gonorrhea
Insurers and antibiotic stewardship
Money for drug-resistance threat
Drug-resistant gonorrhea in Americas
MDR-TB treatment

Apr 21, 2017

Apr 21, 2017

ASP Scan (Weekly) for Apr 21, 2017

Marker for pneumonia antibiotics
MCR-1 cases in Italy
Novel antibiotic target
Penicillin-resistant pneumonia
ID stewardship consults
Steroid for sore throat
MRSA contamination
Chlorhexidine bathing
Candida in Peru
Azithromycin and abnormal heartbeat
Mutations in resistant bacteria

May 13, 2011

May 13, 2011

Study: Pigs susceptible to deadly Ebola strain

(CIDRAP News) – Canadian researchers have shown that an Ebola virus species that can kill humans can also infect pigs and spread among them, raising the specter of Ebola virus as a potential foodborne pathogen.

May 10, 2011

May 10, 2011

FDA approves Sanofi's intradermal flu vaccine

(CIDRAP News) – Sanofi Pasteur's intradermal influenza vaccine, which involves a shallow needle prick into the skin instead of deep into muscle tissue, has been approved by the US Food and Drug Administration (FDA), the company announced today.

Oct 31, 2008

Oct 31, 2008

Encouraging results reported for injectable flu drug

(CIDRAP News) – BioCryst Pharmaceuticals Inc. reported encouraging results this week in two phase 2 trials of its injectable antiviral drug, peramivir, a potential new treatment for influenza.

Peramivir is a neuraminidase inhibitor, like the licensed antivirals oseltamivir (Tamiflu), which is taken orally, and zanamivir (Relenza), inhaled as a powder.

Pages

Sort Results By:

 Sort Results By:

Narrow results by:

by organization

Newsletter Sign-up

Get CIDRAP news and other free newsletters.

Sign up now»

OUR UNDERWRITERS

Unrestricted financial support provided by

Bentson Foundation 3MAccelerate DiagnosticsGilead 
Grant support for ASP provided by

  Become an underwriter»